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ABSTRACT
Some case reports suggest that protein C zymogen supplementation may improve the outcome of patients with congenital 
or acquired protein C deficiency, such as sepsis-induced purpura fulminans. We describe the case report of a patient suf-
fering from meningitis who developed a bleeding complication after recombinant human activated protein C administration 
and was successfully treated without any further bleeding complication with protein C concentrate.
Protein C concentrate can be considered in adult patients with meningitis, even if at risk or in the presence of bleeding.
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Introduction
Because of the significant reduction 
in all-cause mortality, (1) recombinant 
human  activated protein C (rhAPC, 
Xigris, Lilly) was approved for the tre-
atment of adult patients with severe 
sepsis,  at a high risk of death (typically 
APACHE II > 25 or multiple organ failu-
re) and with a low-moderate risk of blee-
ding. (2) In 2012 however, Lilly withdrew 
rhAPC from the market following the 
negative results of the Prowess-Shock 
study. (3) 
Protein C zymogen concentrate (PCc, 
Ceprotin, Baxter) may improve the 
outcome of patients with acquired PC 
deficiency and has been used in chil-
dren, (4,5) and less frequently, in adult 
patients. (6,7)
With ethical committee authorization we 
describe the case report of a patient 
with meningitis who developed a blee-
ding complication during rhAPC admi-
nistration and was successfully treated 
with PCc without any further bleeding 
complications.
Case presentation
A 45 year old patient was admitted to 
the intensive care unit (ICU) of our tea-
ching hospital five hours after presen-
ting to the emergency department with 
meningitis, as documented by coma 
(Glasgow coma scale = 8), pyrexia, 
rigor nucalis, petechiae and severe 
sepsis with hypotension, oliguria, aci-
dosis, dyspnea requiring mechanical 
ventilation, high serum creatinine (2,2 
mg/dL) and C reactive protein (150 
mg/L). Computer tomography of the 
brain was normal and liquor analysis 
revealed proteins and nucleate cells. 
 Broad spectrum antibiotic was started 
(ceftriaxone, ampicillin and acyclovir) 
in association with dexamethasone. 
In spite of aggressive medical thera-
py, (1)  intense fluid resuscitation, and 
increasing doses of norepinephrine up 
to 1.5 g/kg/min, the patient developed 
progressive worsening of tissue perfu-
sion with multiple organ failure (anuria, 
hypotension, hypoxia, acidosis and a 
platelet count of 45 x 109/L).
Eight hours after admission to the ICU, 
the patient was in a life-threatening situ-
ation with multiple organ failure and an 
APACHE II score of 30. He received 
activated protein C (Xigris) at standard 
doses (24 g/kg/h) and vancomicin 
was added to the antibiotic therapy.
Xigris was interrupted after 30 hours of 
continuous infusion because of worse-
ning petechiae and profuse bleeding 
from the mouth and from arterial and 
venous lines insertion sites. The plate-
let count was 10 x 109/L and platelet 
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concentrates were administered. Altho-
ugh the patient had apparently attained 
hemodynamic stability (norepinephrine 
was suspended), he was still in a life 
threatening situation with multiple and 
worsening organ failure. In view  of  the 
platelet count (17 x 109/L), protein C 
plasma levels (20% of normal) and pre-
vious bleeding complications, it was 
decided to start PCc (Ceprotin); a 6000 
IU bolus was followed by a continuous 
infusion of 200 IU/h. Twenty-four hours 
later, protein C was still 35% of normal; 
a  6000 IU PCc bolus was again admi-
nistered and the continuous infusion 
rate increased to 300 IU/h for 62 hours, 
attaining a protein C level of 90% at the 
end of the infusion (figure 1). Figure 2 
shows Prothrombine Time (PT), Activa-
ted Partial Thromboplastin Time (aPTT), 
D-Dimer and fibrinogene levels during 
the study drug infusion. 
Liquor and blood cultures were nega-
tive. The patient was discharged from 
ICU 10 days later and at 30 days was 
an outpatient at  the nephrology depar-
tment because of severe renal failure 
requiring dialysis once a week.
Discussion
This is the first case report that describe 
the use of PCc after a bleeding com-
plication of rhAPC. If the role of PCc in 
adult patients was previously limited to 
patients with bleeding contraindicati-
ons to rhAPC, it is possible that, after 
withdrawal of rhAPC from the market, 
PCc will be used more.
Protein C is a serine protease vitamin K 
dependent zymogen with antithrombo-
tic, antinflammatory and profibrinolytic 
properties. During severe sepsis there 
is a reduction in PC concentration. PC 
deficiency leads to increased activation 
of the coagulation system, resulting 
in thrombin generation and, eventu-
ally, intravascular clot formation with 
thrombosis. (8) Numerous studies have 
demonstrated that decreased circula-
ting levels of PC in septic patients are 
associated with increased morbidity 
and mortality. (9)
PCc is presently utilized as a therapy 
for patients with congenital deficiency 
of PC and for purpura fulminans tre-
atment. In these patients with a high 
risk of bleeding, PCc administration 
seems to be a useful alternative to the 
activated form (rhAPC). Nonetheless, 
in order to recommend the use of PCc 
in the management of severe sepsis 
and septic shock it would be necessary 
to confirm these encouraging findings 
with a randomised multicenter contro-
lled trial.
Updating a systematic search of the 
literature (10) to identify all the PCc 
administrations in adult septic patients, 
we found only 10 papers in the scienti-
fic literature (11 with the present case 
report) accounting for overall less than 
90 patients.
The largest study, reported by Baratto 
et al., (6) described the efficacy and 
safety of PCc for  restoring physiolo-
gical values in 20 adult septic patients 
having clinical contraindications to tre-
atment with rhAPC. They found a signi-
ficant improvement of clinical and coa-
gulation parameters. They observed 
a mortality of 35% while the predicted 
mortality based on SAPS II (55.1±13.2) 
was 58.9%. 
The only randomized study on PCc ever 
published is a dose finding study in a 
pediatric population that was not powe-
red to show an effect on mortality rate 
but did show a positive effect on sepsis 
induced coagulation disturbances. (5)
We conclude that PCc can be conside-
red in patients with meningitis, even if 
at risk or in the presence of bleeding. 
The recent withdrawal from the market 
of rhAPC will probably slightly increase 
its field of application, including adult 
patients.
Figure 2. Variation of coagulation parameters during protein C administration.
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